Primary aldosteronism and aldosterone-associated hypertension

Journal of Clinical Pathology

Volumn 61, Issue 7, 2008, Pages 825-831

  Rayner, B ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CLONIDINE; CORTICOTROPIN; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FLUDROCORTISONE; HYDRALAZINE; INSULIN; METHYLDOPA; PRAZOSIN; RENIN; SODIUM CHLORIDE; SPIRONOLACTONE; TRIACYLGLYCEROL; VERAPAMIL;

ADENOMA; ADRENAL CORTEX; ADRENAL HYPERPLASIA; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE TITRATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; HYPERTENSION; HYPOKALEMIA; INSULIN RESISTANCE; KIDNEY DISEASE; LABORATORY DIAGNOSIS; LABORATORY TEST; LOW DRUG DOSE; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; PLASMA RENIN ACTIVITY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RELIABILITY; RISK FACTOR; SAMPLING; SCINTIGRAPHY; SCREENING; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; ADRENAL GLAND; ADRENAL GLAND NEOPLASMS; CARDIOVASCULAR DISEASES; COMPLICATION; HYPERALDOSTERONISM; HYPERPLASIA; KIDNEY DISEASES; PATHOLOGY;

ADENOMA; ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; CARDIOVASCULAR DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERALDOSTERONISM; HYPERPLASIA; HYPERTENSION; KIDNEY DISEASES; METABOLIC SYNDROME X;

EID: 47049107366     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.053264     Document Type: Article

References (79)

1. Conn JW, Louis LH Primary aldosteronism, a new clinical entity. Ann Intern Med 1956;44:1-15.
2. Conn JW. Plasma renin activity in primary hyperaldosteronism. JAMA 1965;190:222-5.
3. Kaplan NM, Conn JW. Commentary on the incidence of primary hyperaldosteronism. Arch Intern Med 1969;123:152-5.
4. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004;22:863-9.
5. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators. N Engl J Med 1999;341:709-17.
6. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
7. Shah NC, Pringle S, Donnan PT, et al. Spironolactone has antiarrythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens 2007;25:2345-51.
8. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8.
9. Lal A, Veinot JP, Leenen FH. Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. Am J Hypertens 2003;16:319-23.
10. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997;95:1471-8.
11. Choi EY, Ha JW, Yoon SJ, et al. Increased plasma aldosterone-to-renin ratio is associated with impaired left ventricular longitudinal functional reserve in patients with uncomplicated hypertension. J Am Soc Echocardiogr 2008;21:251-6.
12. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005;18:50-5.
13. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kid Dis 2001;37:677-88.
14. Chander PN, Rocha R, Ranaudo J, et al. Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol 2003;14:1990-7.
15. Rossi GP, Bernini G, Desideri G, et al. PAPY Study Participants. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006;48:232-8.
16. Rayner BL, Opie LH, Davidson JS. Aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000;90:387-94.
17. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002;161:1773-81.
18. Beswick RA, Zhang H, Marable D, et al. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001;37:781-6.
19. Pimenta E, Gaddam KK, Pratt-Ubunama MN, et al. Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens 2007;25:2131-7.
20. Ingelsson E, Pencina MJ, Tofler GH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007;116:984-92.
21. Kidambi S, Kotchen JM, Grim CE, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007;49:704-11.
22. Mosso LM, Carvajal CA, Maiz A, et al. A possible association between primary aldosteronism and lower β-cell function. J Hypertens 2007;25:2125-30.
23. Streeten DHP, Anderson GH. Aldosterone disorders. In: Moore WT, Eastman RC, eds. Diagnostic endocrinology. 2nd edn. St Louis: Mosby, 1996:283-98.
24. Gordon RD. Mineralocorticoid hypertension. Lancet 1994;344:240-3.
25. Freel EM, Ingram M, Friel EC, et al. Phenotypic consequences of variation across the aldosterone synthase and 11-β hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT Study. Clin Endocrinol 2007;67:832-8.
26. Newton-Chen C, Guo CY, Gona P, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007;49:846-56.
27. Stowasser M, Gordon RD, Rutherford JC, et al. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2001;2:156-69.
28. So A, Duffy DL, Gordon RD, et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens 2005;23:1477-84.
29. Westerdahl C, Bergenfelz A, Isaksson A, et al. High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden. Scand J Prim Health Care 2006;24:154-9.
30. Fogari R, Preti P, Zoppi A, et al. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 2007;30:111-7.
31. Rossi GP, Bernini G, Caliumi C, et al. PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-300.
32. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981;141:1589- 93.
33. Doi SAR, Abalkhail S, Al-Qudhaiby MM, et al. Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone excess in hypertension. J Hum Hypertens 2006;20:482-9.
34. Tiu SC, Choi CH, Shek CC, et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 2005;90:72-8.
35. Rayner BL, Myers JE, Opie LH, et al. Screening for primary aldosteronism - normal ranges for aldosterone and renin in three South African population groups. S Afr Med J 2001;91:594-9.
36. Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al. Validity of the aldosterone-to-renin ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005;18:805-12.
37. Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of 2 major sub-types. Arch Intern Med 1993;153:2125-9.
38. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005;51:386-94.
39. Ferrari P, Shaw SG, Nicod J, et al. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 2004;22:377-81.
40. McKenna TJ, Sequeira SJ, Heffernan A, et al. Diagnosis under random conditions of all disorders of rennin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991;73:952-7.
41. Gordon RD, Tunny TJ. Aldosterone-producing adenoma (A-P-A): effect of pregnancy. Clin Exp Hypertens A 1982;4:1685-93.
42. Murphy BF, Whitworth JA, Kincaid-Smith P. Malignant hypertension due to an aldosterone producing adrenal adenoma. Clin Exp Hypertens A 1985;7:939-50.
43. Bühler FR, Laragh JH, Baer L, et al. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972;287: 1209-14.
44. Gordon MS, Williams GH, Hollenberg NK. Renal and adrenal responsiveness to angiotensin II: influence of beta adrenergic blockade. Endocr Res 1992;18:115-31.
45. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002;40:897-902.
46. Oparil S. Review of therapeutic modalities acting directly via central pathways. Clin Exp Hypertens A 1982;4:579-93.
47. Manhem P, Hökfelt B. Prolonged clonidine treatment: catecholamines, renin activity and aldosterone following exercise in hypertensives. Acta Med Scand 1981;209:253-60.
48. Gordon RD. Diagnostic investigations in primary aldosteronism. In: Zanchetti A, ed. Clinical medicine series on hypertension. Maidenhead: McGraw-Hill, 2001:101-14.
49. Cappuccio FP, Markandu ND, Sagnella GA, et al. Effects of amlodipine on urinary sodium excretion, rennin-angiotensin-aldosterone system, atrial natiuretic peptide and blood pressure in essential hypertension. J Hum Hypertens 1991;5:115-19.
50. Fiad TM, Cunningham SK, Hayes FJ, et al. Effects of nifedipine treatment on rennin-angiotensin-aldosterone axis. J Clin Endocrinol Metab 1997;82:457-60.
51. Brown MJ, Hopper RV. Calcium-channel blockade can mask the diagnosis of Conn's syndrome. Postgrad Med J 1999;75:235-6.
52. Lamarre-Cliché M, de Champlain J, Lacourciere Y, et al. Effects of circadian rhythms, posture, and medication on rennin-aldosterone interrelations in essential hypertensives. Am J Hypertens 2005;18:56-64.
53. Lyons DF, Kern DC, Brown RD, et al. Single dose captopril as a diagnostic test for primary aldosteronism. J Clin Endocrinol Metab 1983;57:892-6.
54. Guthrie GP Jr, McAllister RG Jr, Kotchen TA. Effects of intravenous and oral verapamil upon pressor and adrenal steroidogenic responses in normal man. J Clin Endocrinol Metab 1983;57:339-43.
55. Leenen FH, Smith DL, Farkas RM, et al. Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. Am J Med 1987;82:969-78.
56. Young WF. Primary aldosteronism: a renaissance of a syndrome. Clin Endocrinol 2007;66:607-18.
57. Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Hypertension 2007;50:447-53.
58. Gordon RD, Ziesak MD, Tunny TJ, et al. Evidence for primary hyperaldosteronism may not be uncommon - 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993;20:296-8.
59. Young WF Jr. Primary aldosteronism: update on diagnosis and treatment. Endocrinologist 1997;7:213-21.
60. Mulatero P, Milan A, Fallo F, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2006;91:2618-23.
61. Rossi GP, Belfiore A, Bernini G, et al. PAPY Study Investigators. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone producing adenoma. J Hypertens 2007;25:1433-42.
62. Giacchetti G, Ronconi V, Lucarelli G, et al. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for standardized protocol. J Hypertens 2006;24:737-45.
63. Blumenfeld JD, Sealey JE, Schlussel Y, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994;121:877-85.
64. Hietakorpi S, Korhonen T, Aro A, et al. The value of scintigraphy and computed tomography for differential diagnosis of primary hyperaldosteronism. Acta Endocrinol 1986;113:118-22.
65. Ma JT, Wang C, Lam KS, et al. Fifty cases of primary hyperaldosteronism in Hong Kong Chinese with a high frequency of periodic paralysis. Evaluation of techniques for tumour localisation. O J Med 1986;61:1021-37.
66. Vaughan NJ, Jowett TP, Slater JD, et al. The diagnosis of primary hyperaldosteronism. Lancet 1981;1:120-5.
67. Mcareavey D, Brown JJ, Cumming AM, et al. Pre-operative localization of aldosterone-secreting adrenal adenomas. Clin Endocrinol 1981;15:593-606.
68. Geisinger MA, Zelch MG, Bravo EL, et al. Primary hyperaldosteronism; comparison of CT, adrenal venography, and venous sampling. Am J Roentgenol 1983;141:299-302.
69. Sheaves R, Goldin J, Reznek RH, et al. Relative value of computed tomography scanning and venous sampling in establishing a cause of primary hyperaldosteronism. Eur J Endocrinol 1996;134:308-13.
70. Radin DR, Manoogian C, Nadler JL. Diagnosis of primary hyperaldosteronism: importance of correlating CT findings with endocrinologic studies. Am J Roentgenol 1992;158:553-7.
71. Mulatero P, Bertello C, Rossato D, et al. Roles of clinical criteria, CT scan and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab 2008;93:1366-71.
72. Quarmby CJ, Burch VC, Dent DM, et al. Conn's syndrome due to adrenocortical adenoma - a rare but rewarding cause of curable hypertension. S Afr Med J 1995;85:1353-6.
73. Hambling C, Jung RT, Browning MC, et al. Primary hyperaldosteronism - evaluation of procedures for diagnosis and localization. O J Med 1993;86:383-92.
74. Cantena C, Colussi G, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007;50:911-8.
75. Auchus RJ, Drazner MH. Will the lessons from primary aldosteronism change the treatment of hypertension and left ventricular hypertrophy? Hypertension 2007;50:837-9.
76. Sartori M, Calò LA, Mascagna V, et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 2006;19:373-9.
77. Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow up study. Br J Clin Pharmacol 1999;48:756-60.
78. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007;25:891-4.
79. Hood SJ, Taylor KP, Ashby MJ, et al. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007;116:268-75.